PLx Pharma Inc (PLXP) Receives Consensus Rating of “Buy” from Analysts
Shares of PLx Pharma Inc (NASDAQ:PLXP) have been assigned an average broker rating score of 2.00 (Buy) from the one analysts that provide coverage for the stock, Zacks Investment Research reports. One analyst has rated the stock with a buy recommendation.
Analysts have set a 1-year consensus target price of $12.00 for the company, according to Zacks. Zacks has also given PLx Pharma an industry rank of 111 out of 265 based on the ratings given to related companies.
Several equities research analysts have commented on the stock. Zacks Investment Research cut shares of PLx Pharma from a “buy” rating to a “hold” rating in a research report on Saturday, August 19th. ValuEngine upgraded shares of PLx Pharma from a “strong sell” rating to a “sell” rating in a research note on Monday, December 4th.
Several institutional investors have recently added to or reduced their stakes in PLXP. University of Texas Investment Managment Co. acquired a new position in shares of PLx Pharma during the 2nd quarter worth about $385,000. Susquehanna International Group LLP acquired a new position in shares of PLx Pharma during the 2nd quarter worth about $1,413,000. Finally, Harel Insurance Investments & Financial Services Ltd. acquired a new position in shares of PLx Pharma during the 3rd quarter worth about $145,000. Institutional investors own 21.87% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another domain, it was illegally copied and reposted in violation of US & international copyright & trademark law. The correct version of this report can be accessed at https://www.watchlistnews.com/plx-pharma-inc-plxp-receives-consensus-rating-of-buy-from-analysts/1757797.html.
PLx Pharma Company Profile
PLx Pharma Inc, formerly Dipexium Pharmaceuticals, Inc, is a biopharmaceutical company. The Company is a late stage specialty pharmaceutical company focusing on commercializing its lead products: Aspertec 325 mg and Aspertec 81 mg (Aspertec). The Company’s products and technology includes PLxGuard delivery system, Aspertec 325 mg, PL1100/PL1200 Ibuprofen.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for PLx Pharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PLx Pharma Inc and related companies with MarketBeat.com's FREE daily email newsletter.